Sunshine Pharma (Sunshine Lake Pharma Co., Ltd.) has dispatched its inaugural commercial shipment of Insulin Glargine Injection (brand name: Langlara) to the United States, marking the first time a Chinese pharmaceutical company has commercialised an insulin glargine product in this market. The initial lot totals approximately 1.15 million prefilled pens and will be delivered in phases, with completion targeted by mid-to-late August 2026.
The shipment follows the U.S. Food and Drug Administration’s approval of Langlara in late April 2026. The product is the fourth insulin glargine therapy cleared for sale in the United States and has been granted “interchangeable biosimilar” status, allowing pharmacy-level substitution for the reference drug without a new prescription—an advantage expected to ease market access and accelerate uptake.
Market data from QYResearch place the global insulin glargine segment at nearly USD 10 billion, with the United States accounting for more than 60% of demand, underscoring the commercial significance of Sunshine Pharma’s entry.
Sunshine Pharma now counts six approved insulin products in China, following 30 July 2026 domestic approval of its Insulin Degludec Injection (cartridges and prefilled pens). The broader pipeline includes an Insulin Degludec/Insulin Aspart combo under registration review and HEC-151, an ultra-long-acting weekly insulin formulation in Phase I clinical trials, forming an evolving “daily–weekly–combination” product suite.
Manufacturing capacity is underpinned by the company’s Yidu City (Hubei) facility, which integrates the full insulin value chain and can produce more than 100 million units of insulin drug products annually. The U.S. shipment represents the first tranche of a previously secured order for no fewer than 18 million units from an American partner.
Beyond the United States, Sunshine Pharma has secured approvals for glargine insulin in the United Arab Emirates, Bahrain, Algeria, Mali and Niger; for aspart insulin in the United Arab Emirates, Bahrain, Algeria and Niger; and for aspart insulin 30 in the United Arab Emirates and Bahrain. Clinical trial applications for insulin degludec biosimilars are planned in the United States and Europe, complementing ongoing expansion into North and West Africa, South-East Asia and South America.
The commencement of U.S. deliveries signifies a pivotal advancement in Sunshine Pharma’s overseas commercialisation strategy and reinforces the global trajectory of China-developed insulin biosimilars.
Comments